Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
1998-11-19
2001-05-29
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C435S188000, C435S963000, C435S390000, C530S387100, C530S350000, C530S380000, C424S177100
Reexamination Certificate
active
06238664
ABSTRACT:
FIELD OF THE INVENTION
This invention is in the field of proteins and protein solutions.
BACKGROUND OF THE INVENTION
Proteins such as enzymes or antibodies as well as fragments thereof are unstable and susceptible to loss of activity and/or to formation of soluble or insoluble aggregates in aqueous solutions and when stored at low temperatures (below 0° C.) and in particular in repeated freezing and thawing processes and these aggregates become apparent by forming particles and thus as turbidities. However, such aggregate and/or particle formation cannot be tolerated or at least only in traces for pharmaceutical compositions of proteins. A pharmaceutical composition should be a clear solution and if it is present as a lyophilisate it should also lead to a clear particle-free solution when reconstituted which is also free of soluble protein aggregates.
Numerous processes and additives are known for the stabilization of proteins in solutions. For example the stabilization of proteins by adding heat-shock proteins such as HSP25 is for example described in EP-A 0 599 344. The stabilization of antibodies by adding block polymers composed of polyoxy-propylene and polyoxy-ethylene and by phospholipids is described in EP-A 0 318 081. EP-A 0 025 275 describes the stabilization of immunoglobulin by adding a salt of a basic substance containing nitrogen such as arginine, guanidine or imidazole. Other suitable additives for stabilization are polyethers (EP-A 0 018 609), glycerin, albumin and dextran sulfate (U.S. Pat. No. 4,808,705), detergents such as Tween®20 (DE 26 52 636, GB 8514349), chaperones such as GroEL (Mendoza, J. A. Biotechnol. Tech. 10 (1991) 535-540), citrate buffer (WO 93/22335) or chelating agents (WO 91/15509). Although these additives enable proteins to be stabilized to a certain extent in aqueous solutions. It has, however, turned out that none of the processes known in the prior art is suitable for stabilizing proteins during repeated freezing and thawing processes in such a way that no soluble or insoluble aggregates or only negligible amounts for therapeutic purposes are formed during rethawing, during storage at temperatures below 0° C. or when a solution is reconstituted after lyophilization.
In EP-A 0 314 095 a lyophilisate of a plasma protein such as factor VIII is described which contains histidine buffer as a buffer substance and calcium chloride as an additive and is present in a high ionic strength (0.35 to 1.2 mol/l NaCl).
A lyophilisate of a plasma protein such as factor VIII is described in EP-A 0 315 968 which contains 0.5 to 15 mmol/l sodium chloride or potassium chloride, 0.01 to 10 mmol/l lysine hydrochloride and 0.2 to 5 mmol/l histidine as a buffer ion. However, histidine buffer is not suitable for stabilizing proteins and for preventing aggregate and particle formation when lyophilisates of proteins are reconstituted.
SUMMARY OF THE INVENTION
This invention provides a composition comprising an aqueous buffered solution having a protein dissolved therein, wherein the solution contains potassium ions and either contains no sodium ions or contains sodium ions such that the ratio of potassium ions to sodium ions in the solution is at least 10:1; the solution being buffered with a potassium phosphate buffer.
This invention further provides a process for forming an aqueous buffered solution having a protein dissolved therein comprising: dissolving the protein in an aqueous solution; and adjusting the aqueous solution with a potassium phosphate buffer so that the aqueous solution having the protein dissolved therein contains potassium ions and either contains no sodium ions or contains sodium ions such that the ratio of potassium ions to sodium ions in the solution is at least 10:1.
The aqueous buffered protein solution of this invention is resistant to the formation of protein aggregation and particle formation under conditions of freezing, thawing, lyophilization, and reconstitution. Reduction of protein aggregation and particle formation is desirable during the manipulation of protein solutions generally, to reduce loss of protein and protein activity. It is also desirable in pharmaceutical uses, in which limiting the number of aggregates is particularly important.
REFERENCES:
patent: 4783441 (1988-11-01), Thurow
patent: 5429928 (1995-07-01), Blaustein et al.
patent: 0 018 609 (1980-11-01), None
patent: 0 025 275 (1981-03-01), None
patent: 0 314 095 (1989-05-01), None
patent: 0 315 968 (1989-05-01), None
patent: 0 318 081 (1989-05-01), None
patent: 0671410A1 (1995-09-01), None
patent: 0670328A1 (1995-09-01), None
Derwent Abstract AN 98-555428 Abstract only Yu, R.M. et al RU 2109290 Apr. 20, 1998.
Chemical Abstracts No. 195334 Abstract only Heller MC et al 1997 Biotechnology Prog 13:590-596.
Heller, Biotechnol. Prog. 13 pp. 590-596 (1997).
Hwang, et al, Effect of Phosphate salts on the emulsion stability of soy protein isolate, J. Kor. Agric. Chem. Soc., vol. 35, No. 3, pp. 152-156 (1992).
Hellerbrand Klaus
Papadimitriou Appollon
Winter Gerhard
Boehringer Mannheim GmbH
DeCloux Amy
Epstein William H.
Johnston George W.
Saunders David
LandOfFree
Process for stabilizing proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for stabilizing proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for stabilizing proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2497526